Drug Coated Balloon vs. Drug-eluting Stent in Patients With Coronary Artery Disease

Starting soon

Conditions studied: Coronary Artery Disease, Percutaneous Coronary Intervention (PCI)

In brief

Studies exploring the feasibility of drug-eluting balloon (DCB) in de-novo coronary lesions are limited. There are scarce data comparing DCB with drug-eluting stent (DES) in patients with high bleeding risk (HBR), a situation in which long-term maintenance of dual antiplatelet therapy (DAPT) is a clinical dilemma. This target trial emulation aims to compare clinical outcomes between DCB angioplasty and conventional DES implantation in de-novo coronary lesions in patients with coronary artery disease.

Key facts

Study ID

NCT07442500

Run by

Samsung Medical Center

People needed

470000

Starts

2026-02-28

Expected to finish

2026-12-31

Last updated by the study team

2026-03-02

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with coronary artery disease undergoing percutaneous coronary intervention
• Used devices number less than three (relatively simple lesion)

You may not qualify if…

• Hybrid strategy (DCB and DES use)
• Failed percutaneous coronary intervention
• Previous revascularization procedure before index percutaneous coronary intervention

Where it is running

• Samsung Medical Center — Seoul, South Korea

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.